OpenAI says it filed confidential IPO as it positions itself for AI arms race Ivar AI

Elespanol.com

Irán ataca Israel en represalia por su ofensiva sobre Líbano: Trump pide a Netanyahu no replicar para evitar la escalada

Forbes

Global AI Buildout Proves Wealth Lode For Its Picks-And-Shovels Billionaires In Taiwan

Businessam.be

Italiaanse bank Intesa Sanpaolo kan dankzij overname op één na grootste bank van Europa worden

Crypto Briefing

US Central Command intercepts Iranian missiles, strikes radar sites in Strait of Hormuz escalation

The Daily Caller

China Pours More Fuel On The AI Arms Race Fire

Crypto Briefing

Iran allegedly shoots down US Army Apache helicopter near Oman, triggering retaliatory strikes

Crypto Briefing

Binance integrates 7,000 US stocks and ETFs into app alongside crypto trading

PRNewswire

TeamSystem finaliza su plan de inversión en IA de 250 millones de dólares un año antes de lo previsto

Foreign Policy

Trump Says More Strikes on Iran Are Coming

New York Post

Meta and Mike Rowe launch $115 trade-training program that guarantees jobs to future welders, plumbers, electricians

The Times of India

Gulf countries act as propellants for SpaceX IPO as billions flow in

Yahoo Entertainment

幫馬斯克撈火箭！27歲的她有望變億萬富豪　靠「1大膽決定」迎SpaceX上市

Crypto Briefing

American Bitcoin grows BTC balance sheet to 7,021 coins, cites 50% mining margin

The Times of India

U.S. spending on rebuilding nuclear arsenal more than all other nuclear states combined including China, Russia

Yahoo Entertainment

美股屠殺外溢亞股，KOSPI早盤狂瀉8.37%，三星、SK海力士遭血洗

Orf.at

US-Armee meldet neue Angriffe auf Iran

NPR

U.S. military says it's striking 'multiple targets' in Iran in 2nd day of renewed fire

Noticiabrasil.net.br

Concessão de hidrovias destrava potencial logístico há décadas ignorado no Brasil, avaliam analistas

$Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire$

GlobeNewswire

Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire